ProKidney Corp. (PROK)
$1.57-5.99%Close
SELLCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $233M
- Beta
- 1.80
- P/E (TTM)
- -2.75
- Short % float
- 21.86%
- Days to cover
- 11.0
- SI change
- +10.9%
- 1W
- -1.88%
- 1M
- -13.26%
- vs SPY 1W
- -1.74%
- vs SPY 1M
- -15.77%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 8
- GROWTH
- 0
- GARP
- 1
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC5.3%
REV YoY-
ROE8.8%
EPS YoY-
ROA-34.8%
GROSS-253
OP-21665
NET-10600
[VALUATION]
P/E TTM-2.75
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B-0.33
P/FCF-
EV/EBITDA-2.86
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO8.36
ND/EBITDA-
BETA1.80
Company news
FAQ
- What is LOPJLB’s current signal on PROK?
- LOPJLB’s latest quantitative signal on ProKidney Corp. (PROK) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is PROK in?
- ProKidney Corp. (PROK) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does ProKidney Corp. (PROK) do?
- ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals…